BriaCell Therapeutics (CVE:BCT) Stock Price Down 3.8% – Should You Sell?

BriaCell Therapeutics Corp. (CVE:BCT)’s stock price traded down 3.8% during trading on Tuesday . The stock traded as low as C$10.60 and last traded at C$10.60. 3,402 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.

BriaCell Therapeutics Stock Down 3.8%

The firm has a 50-day simple moving average of C$10.60 and a 200 day simple moving average of C$10.60. The company has a market capitalization of C$168.68 million and a PE ratio of -28.19. The company has a debt-to-equity ratio of 0.05, a current ratio of 129.63 and a quick ratio of 128.68.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.